Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Elphis Cell Therapeutics has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are spread among 3 examiners and 3 art units, giving each pending matter a separate apparent examination assignment.
TICHY, JENNIFER M.H. is the busiest examiner, with 1 pending matter. Counsel should preserve matter-specific response strategies while monitoring for recurring issues across the separate assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TICHY, JENNIFER M.H. | 1 | 64.6% | +34.4% |
| PAULUS, ERIN VIRGINIA | 1 | 20.0% | +94.1% |
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286954 | COMPOSITION CONTAINING MESENCHYMAL STEM CELL AND VASCULAR ENDOTHELIAL PROGENITOR CELL AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF OCCLUSIVE VASCULAR DISEASE OR COMPLICATION THEREOF | TICHY, JENNIFER M.H. | — |
| 18278915 | METHOD FOR PREPARING BONE-MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS HAVING INCREASED VASCULOGENESIS BY USING PDGF-BB, AND METHOD FOR PREPARING CELL THERAPEUTIC AGENT FOR TREATING ANANGIOPLASIA-RELATED DISEASES BY USING METHOD | PAULUS, ERIN VIRGINIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286954 | COMPOSITION CONTAINING MESENCHYMAL STEM CELL AND VASCULAR ENDOTHELIAL PROGENITOR CELL AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF OCCLUSIVE VASCULAR DISEASE OR COMPLICATION THEREOF | TICHY, JENNIFER M.H. | — |
| 18278915 | METHOD FOR PREPARING BONE-MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS HAVING INCREASED VASCULOGENESIS BY USING PDGF-BB, AND METHOD FOR PREPARING CELL THERAPEUTIC AGENT FOR TREATING ANANGIOPLASIA-RELATED DISEASES BY USING METHOD | PAULUS, ERIN VIRGINIA | — |
| 18014554 | COMBINATION THERAPY OF SUBSTANCE-P FOR MOBILIZATION OF HEMATOPOIETIC STEM CELLS | BELYAVSKYI, MICHAIL A | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1631 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18286954 | COMPOSITION CONTAINING MESENCHYMAL STEM CELL AND VASCULAR ENDOTHELIAL PROGENITOR CELL AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF OCCLUSIVE VASCULAR DISEASE OR COMPLICATION THEREOF | TICHY, JENNIFER M.H. | 1653 | §102§103§112 | Final Rejection | — | Pending | Oct 13, 2023 |
| 18278915 | METHOD FOR PREPARING BONE-MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS HAVING INCREASED VASCULOGENESIS BY USING PDGF-BB, AND METHOD FOR PREPARING CELL THERAPEUTIC AGENT FOR TREATING ANANGIOPLASIA-RELATED DISEASES BY USING METHOD | PAULUS, ERIN VIRGINIA | 1631 | §102§103§112 | Final Rejection | — | Pending | Aug 25, 2023 |
| 18014554 | COMBINATION THERAPY OF SUBSTANCE-P FOR MOBILIZATION OF HEMATOPOIETIC STEM CELLS | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | — | Pending | Jan 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialElphis Cell Therapeutics has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Jennifer M.H. Tichy has the most, with 1 of Elphis Cell Therapeutics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
